Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABVX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| ABX203 therapeutic Hepatitis B vaccine t | Chronic Hepatitis B | Phase 2/3 · NCT02249988 | Completed |
| Obefazimod | Ulcerative Colitis | Phase 3 · NCT05535946 | Active not recruiting |
| iNKT Cell Agonist ABX196 | Carcinoma, Hepatocellular | Phase 1/2 · NCT03897543 | Completed |
| ABX464 Repeated dose | Healthy Volunteers | Phase 1 · NCT02731885 | Completed |
| ABX464 Single dose | Healthy Volunteers | Phase 1 · NCT02731885 | Completed |
| Fluvoxamine | Healthy | Phase 1 · NCT05121714 | Completed |
| Obefazimod Minitablet 50 mg | Healthy | Phase 1 · NCT07453784 | Recruiting |
Also used in these trials (approved or third-party drugs, not ABVX's own candidates): Methotrexate, Caffeine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABVX holds $402.4M in cash and short-term investments and burns about $49.3M/quarter from operations, an estimated runway of 24.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 7 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABVX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Chen Yu | 5%+ holder (13G) | 6,007,834 | 7.65% | 2026-06-30 |
| TCG Crossover Management, LLC | Institution (13F) | 6,007,834 | 7.65% | 2026-06-30 |
| Raymond Debbane | 5%+ holder (13G) | 4,825,759 | 6.14% | 2026-06-30 |
| Invus Public Equities, L.P. | 5%+ holder (13G) | 3,922,995 | 5.00% | 2025-12-31 |
| Darwin Global Management, Ltd. | Institution (13F) | 3,621,583 | 4.61% | 2026-06-30 |
| Helikon Investments Ltd | Institution (13F) | 2,787,131 | 3.55% | 2026-06-30 |
| Vestal Point Capital, LP | Institution (13F) | 2,349,443 | 2.99% | 2026-06-30 |
| Jupiter Topco LLC | Institution (13F) | 1,913,933 | 2.44% | 2026-06-30 |
| UBS Group AG | Institution (13F) | 1,844,918 | 2.35% | 2026-06-30 |
| Adar1 Capital Management, LLC | Institution (13F) | 1,804,703 | 2.30% | 2026-06-30 |
| Caligan Partners, LP | Institution (13F) | 1,557,924 | 1.98% | 2026-06-30 |
| Citadel Advisors Llc | Institution (13F) | 1,438,352 | 1.83% | 2026-06-30 |
Share count 78,536,412 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABVX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →